Drugs / GB268
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06934616 | Apr 2025 → Mar 2027 expected | — | Genor Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | Eddingpharm (Zhuhai) Co., Ltd. | Results 亿腾嘉和多款产品研究成果即将公布 创新研发实力再上台阶 eddingpharm.com ↗
截至2026年7月17日，GB268一期临床研究数据显示，在后线乳腺癌和非小细胞肺癌的患者中观察到了令人鼓舞的疗效。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | Eddingpharm (Zhuhai) Co., Ltd. | 亿腾嘉和多款产品研究成果即将公布 创新研发实力再上台阶 eddingpharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB268 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06934616 ↗ |
| Modality | Monoclonal antibody | “Trispecific PD-1/CTLA-4/ VEGF Antibody GB268” NCT06934616 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT06934616 ↗ |